US Venture Partners led a $65m Series F round in MicroTransponder.

US Venture Partners, a venture capital financing company, led a $65m Series F round in MicroTransponder, a biotechnology company, with participation from Osage University Partners, Action Potential Venture Capital, GPG Ventures, The Vertical Group, Exceller Hunt Ventures, Gilde Healthcare and Longitude Capital. "We've built programs in 20% of Joint Commission Comprehensive Stroke Centers and 50% of Becker's 2024 100 Great Neuro and Spine Programs by presenting Vivistim as the evidence-based chronic stroke recovery solution that's been missing from the stroke continuum of care. In partnership with leading healthcare providers, we've helped build new programs that support our goal of changing the standard of care for stroke treatment across the US, renewing hope for stroke survivors and their caregivers," Richard Foust, MicroTransponder CEO.